Clinical trial · Observational
RW Effectiveness of Lurbinectedin in Extensive Stage SCLC
Real-world Effectiveness and Treatment Sequences in Patients With Extensive Stage SCLC Who Received Lurbinectedin as Part of the French Early Access Program (ATU).
NCT05285033CI-TRIAL-00063061LURBICLINcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
LURBICLIN cohort will describe the demographic and clinical characteristics of patients who received at least one dose of lurbinectedin as part of ATU program. LURBICLIN will evaluate effectiveness and safety of lurbinectedin in real-world conditions.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Small-cell Lung Cancer | Lung Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Lurbinectedin | Drug | Lurbinectedin | ALIAS |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- demographic and clinical characteristics of patients
- timeFrame
- 8 months
- description
- age
- measure
- demographic and clinical characteristics of patients
- timeFrame
- 8 months
- description
- sex
- measure
- demographic and clinical characteristics of patients
- timeFrame
- 8 months
- description
- clinical stage
- measure
- demographic and clinical characteristics of patients
- timeFrame
- 8 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with histologically or cytologically confirmed extensive stage Small Cell Lung Cancer * Patients who were informed about the study and accepted for their data to be collected * Patients who received at least one dose of treatment with lurbinectedin as part of the French Early Access Program (ATU program). * Selection period spans from June 2020 until March 2021 for initiation of treatment with lurbinectedin. Exclusion Criteria: * Patients enrolled in a clinical trial assessing treatment with lurbinectedin
References
Publications (1)
- BACKGROUNDTrigo J, Subbiah V, Besse B, Moreno V, Lopez R, Sala MA, Peters S, Ponce S, Fernandez C, Alfaro V, Gomez J, Kahatt C, Zeaiter A, Zaman K, Boni V, Arrondeau J, Martinez M, Delord JP, Awada A, Kristeleit R, Olmedo ME, Wannesson L, Valdivia J, Rubio MJ, Anton A, Sarantopoulos J, Chawla SP, Mosquera-Martinez J, D'Arcangelo M, Santoro A, Villalobos VM, Sands J, Paz-Ares L. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. Lancet Oncol. 2020 May;21(5):645-654. doi: 10.1016/S1470-2045(20)30068-1. Epub 2020 Mar 27. PMID 32224306